Tom Daniel was President, Global Research and Early Development at Celgene Corporation over the last decade, as the company emerged as a leader in defining new mechanisms for drug action, established industry leading collaborative networks, and advanced and commercialized innovative medicines in oncology and inflammatory diseases. He previously served as Chief Scientific Officer and Director of AmbRx, as Vice President of Research at Amgen, and as Senior Vice President of Discovery Research at Immunex Corporation.
Tom is currently Chairman at Vividion Therapeutics, a director at Juno Therapeutics, VIR Biotechnology, Magenta Therapeutics, ImmunsanT and Zafgen. He is a member of the scientific steering committee at the Parker Institute for Cancer Immunotherapy. He is a Trustee of Reed College, and serves on the Board of the Alliance for Lupus Research, on the Biomedical Science Advisory Board of Vanderbilt University Medical Center, and is a senior advisor to BlackThorn Therapeutics. A nephrologist and former academic investigator, Tom was previously C.M. Hakim Professor of Medicine and Cell Biology at Vanderbilt. He earned his medical degree from the University of Texas, Southwestern, trained in molecular genetics at UTSW, and completed a medical residency at Massachusetts General Hospital.